BK2428 Drug Manufacturers - General
- 1666.615
- +1.638+0.10%
J&J-backed Rapport Therapeutics Files for $100M IPO
Larimar Stock Rallies 24% on FDA Removal of Partial Clinical Hold
How Is The Market Feeling About Biogen?
Biogen's (NYSE:BIIB) short percent of float has fallen 3.56% since its last report. The company recently reported that it has 3.15 million shares sold short, which is 2.44% of all regular shares that
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COP
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 150 points on Monday.The Dow traded down 0.43% to 39,831.18 while the NASDAQ rose 0.53% to 16,775.01. The
Regeneron Pharmaceuticals And Sanofi Present Late-Breaking Data From NOTUS Confirmatory Phase 3 COPD Trial Of Use Of Dupixent; Presented At ATS And Published In New England Journal of Medicine
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic
Pfizer Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Pfizer.Looking at options history for Pfizer (NYSE:PFE) we detected 13 trades.If we consider the specifics of each trade,
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market ca
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents
Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty
AstraZeneca, Amgen Release Mid-stage Data on Tezspire for COPD
Johnson & Johnson's Tremfya Meets Goals in Late-stage Trial for Ulcerative Colitis
AstraZeneca to Build $1.5B ADC Manufacturing Plant in Singapore
Mira Pharmaceuticals Shares Are Trading Higher After the Company Said It Has Advanced New Preclinical Studies Using Ketamir-2 Towards Clinical Development.
Mira Pharmaceuticals Shares Are Trading Higher After the Company Said It Has Advanced New Preclinical Studies Using Ketamir-2 Towards Clinical Development.
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study.The ASSURE study is an open-label stu
Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission
Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative
Witness history! The Dow closed above 40,000 points for the first time. Apart from constituent stocks, these ETFs are also worth watching
Buffett once said, “By regularly investing in index funds, an amateur investor who doesn't understand anything can often beat most professional investors.”
AstraZeneca Plans $1.5B Manufacturing Facility For Antibody Drug Conjugates In Singapore, AstraZeneca Expects To Begin Design And Construction By The End Of 2024, With Targeted Operational Readiness From 2029
AstraZeneca Plans $1.5B Manufacturing Facility For Antibody Drug Conjugates In Singapore, AstraZeneca Expects To Begin Design And Construction By The End Of 2024, With Targeted Operational Readiness F
Reported Saturday, Gilead Sciences Announced That The Investigational Seladelpar Shows Significant Improvements In Liver Disease Progression And Itch Reduction In Primary Biliary Cholangitis
- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -- Reduction in Patient-Reported Pruritus (Itching) wa